SCHEMBL5743569

SCHEMBL5743569

CCOC(=O)c1cc[n+]([O-])cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 1/20 0.44
CA12 O43570 4/20 0.42
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
CA14 Q9ULX7 4/20 0.42
LMNA P02545 5/20 0.42
L3MBTL1 Q9Y468 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C19 P33261 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3514702 0.88 TSHR (0.56) TSHRALDH1A1HSD17B10CA12CA1
SCHEMBL27006674 0.87 TSHR (0.50) TSHRALDH1A1HSD17B10CA12CA1
SCHEMBL31184835 0.83 MAPT (0.48) TSHRALDH1A1HSD17B10CA12CA1
SCHEMBL31184904 0.83 MAPT (0.48) TSHRALDH1A1HSD17B10CA12CA1
SCHEMBL28250511 0.77 ALDH1A1 (0.48) TSHRALDH1A1LMNAKDM4EKMT2A
SCHEMBL3659496 0.77 MEN1 (0.46) TSHRALDH1A1HSD17B10LMNAKDM4E
SCHEMBL14738587 0.77 MEN1 (0.46) TSHRALDH1A1HSD17B10LMNAKDM4E
SCHEMBL23727297 0.76 TSHR (0.46) TSHRALDH1A1HSD17B10CA12CA1
SCHEMBL4873097 0.75 CA12 (0.58) ALDH1A1CA12CA1CA2CA7
SCHEMBL4862698 0.73 GLA (0.57) TSHRALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
EP-1404672-B1 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2006-01-18 EP disclosed
US-6875767-B2 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors MERCK & CO., INC. (US) 2005-04-05 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
US-20030100567-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2003-05-29 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC TSHR 1383/4885ALDH1A1 1345/4885HSD17B10 345/4885
US-20030100567-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 TSHR 1987/4885ALDH1A1 3104/4885HSD17B10 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.